Dural angioleiomyoma: a new tumour type with frequent GJA4 mutation and a distinct DNA methylation profile
08:00Thibaut Pierre, Paris / FR
3
Clinical applicability of whole brain SLOW-editing compared to MEGA-editing for the evaluation of the IDH-mutation status in glioma patients at 7T
08:00Guodong Weng, Bern / CH
4
Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas
08:00Arian Lasocki, Melbourne / AU
5
Clinical and pathologic characteristics of long-term oligodendroglioma survivors
08:00Brian Nan, Valhalla / US
6
The impact of tumour location on survival in glioblastoma patients
08:00Ahmad Amer, CHICAGO / US
7
Histologic validation of multi-echo perfusion MRI to evaluate brain tumour microstructure
08:00Francesco Sanvito, Pavia / IT
8
Radiological and pathological predictors of post-surgical evolution of pituitary neuroendocrine tumours. A retrospective analysis of 125 patients
08:00José Miguel Castro, Alicante / ES
9
Comparative diagnostic accuracy of amide proton transfer-weighted imaging and dynamic susceptibility contrast perfusion in the distinction between brain radiation necrosis and tumour progression
08:00Mehdi Bensemain, Nancy / FR
10
Introduction of intra-arterial administration of [68Ga]Ga-PSMA and [68Ga]Ga-DOTA-TATE in CNS tumors; a high potential approach for future development of novel theranostic treatment strategies
08:00Sophie Veldhuijzen van Zanten, Rotterdam / NL
11
Do we match? An evaluation of the T2/FLAIR mismatch sign for oligodendroglioma diagnosis
08:00Julia Brunelli, Sao Paulo / BR
12
Effect of radiation therapy on meningioma enhancement on PET CT